oncolex logo
Utskriftsdato 15.11.2018

Referanser til føflekkreft

    1. Cancer in Norway 2016, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway.
    2. de Vires E & Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355–66.
    3. de Vires E , Bray F, Coebergh JW in DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1967–1997: rising trends in incidence and mortality, but stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003; 107: 119–26.
    4. Marghoob AA. Large congenital melanocytic nevi and the risk for the development of malignant melanoma. Arc Dermatol 1996; 132: 170–5.
    5. Rockley PF. Non risk factors for malignant melanoma. Chemical agents, physical conditions and occupation. Int J Dermatol 1994; 33: 398–405.
    6. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trail. JAMA 1998; 280: 1485–9.
    7. Huber MR, Markovic SN. Adjuvant nodal radiotherapy for node positive head and neck melanoma: A single institution experience. Proc Am Soc Clin Oncol 2004; 23: 716, abstract 7537
    8. Kraehn GM, Schartl M, Peter RU. Human malignant melanoma. A genetic disease? Cancer 1995; 75: 1228–37.
    9. Balch CM, Houghton AN, Milton GW et al. red. Cutaneous melanoma. 2. utg. Philadelphia: Lippincott, 1992: 165–86.
    10. Massback A, Olsson H, Westerdahl J et al. Prognostic factors in invasive cutaneous malignant melanoma: a population-based study and review. Melanoma Res 2001; 11: 435–45
    11. Seregard S. Posterior uvealt melanoma. The Swedish perspective. Acta Ophthalmol Scand 1996; 74: 315–329
    12. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av maligne melanomer (10/2017), Helsedirektoratet
    13. Balch CM, Gershenvald JE, Soony SJ, Thompson JF, Atkins MB, Byrd DR et al. Final versjon of 2009 AJCC melanoma staging and classification. J.Clin Oncol 2009; 27 (36):  6199-206
    14. Danson SJ, Middleton MR. temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther 2001; 1: 13-9.
    15. Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008; 5: 557-61.
    16. Hodi FS, O`Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
    17. Kullavanijaya, P, Lim HW. Photoprotection. J Am Acad dermatol 2005, 52(6): 937-58.
    18. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use randomized trial follow-up. J Clin Oncol 2011; 29 (3): 257-63.
    19. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers. A systematic review. Int J Cancer 2007; 120 (5): 1116-22.
    20. Eapen S, Dutcher JP. A review of evidence-based treatment of stage IIB to stage IV melanoma. Cancer Invest 2005; 23: 323-37.
    21. Verma S, Quart I, McCready et al. Systemic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006; 106: 1431-42.
    22. Tawbi HA, Kirkwood J. management of metastatic melanoma. Semin Oncol 2007; 34: 532-45.
    23. Middelton MR, Grob JJ, Aaronson N et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic  melanoma. J Clin Oncol 2000; 18: 158-66.
    24. Kadison AS, Morton DL. Immuntherapy of malignant melanoma. Surg  Clin North Am 2003; 83: 343-70.
    25. Agarwala SS, Kirkwood JM. Update on adjuvant interferon therapy for high-risk melanoma. Oncology 2002; 16: 1177-87, discussion 90-2, 97.
    26. Hamm C, verma S, Petrella T et al. Biochemotherapy for the treatment of metastatic malignant melanioma. A systematic review.Cancer Treat Rev 2008;34: 145-56.
    27. Wolchok JD, Kluger H, Callahan K et al. Nivolumab plus ipilimumab in advanced melanoma. new Engl J Med 2013; 369: 122-33.
    28. Fenig E, Eidelevich E, Njugana E, et al. Role of Radiation Therapy in the Management of Cutaneous Malignant Melanoma. Am J Clin Oncol 1999; 2: 184–6.
    29. Noel G, Simm JM, Valery C-A et al. Linac radiosurgery for brain metastasis of meloma. Stereotact Funct Neurosurg 2002; 79: 245-255. 
    30. Waldeland E, Brustugun OT, Ramberg C, Helland Å. Stereotaktisk bestråling av columnametastaser. Tidsskr Nor Lægeforen 2012; 132: 2478-9.
    31. Xing Y, Bronstein Y, Ross M, et al. Contemorary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011; 103 (2): 129-42.
    32. Jimenez-Requena F, Delgado-Bolton RC, Fernandez-Perez C et al. Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. Eur J Nucl Med Mol Imaging 2010; 37(2): 284-300.
    33. Lejeune FJ, Kroon BB, Di Filippo F et al. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001; 10: 821-32.

    34. Ricotti F, Giuliodori K, Cataldi I et al.Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous melanoma metastases. Dermatol Ther. 2014 May-Jun; 27 (3): 148-52.
    35. Queirolo P, Marincola F, Spagnolo F. Electrochemotherapy for the management of melanoma skin metastases: a review of the literature and possible combinations with immuntherapy. Arch Dermatol Res. 2014 Aug: 306(6): 521.6.

    36. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.

    37. Chapman PB, Hauschild A, Robert C. Improved survival with Vemurafenib in melanoma with BRAF V600 mutation.N Engl J Med 2011; 364: 2507-2516.

    38. Flaherty  KT,  Puzanov  I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma.N Engl j Med 2010; 363: 809-819.

    39. Mendenhal  WM, Amdur RJ, Grobmyer SR et al. Adjuvant radiotherapy for cutaneous melanoma. Cancer 2008; 112: 1189-96.
    40. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int. J Cancer 1997;73(2):198-203.
    41. Kreftforeningens og Statens Strålevern, Fitxpatrick hudtypeklassifisering.
    42. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11(3):255-263.
    43. AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing.
    44. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma, Faries MB et al. N Engl J Med 2017; 376:2211-2222June 8, 2017DOI: 10.1056/NEJMoa1613210.
    45. CheckMate 238 studien.
    46. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16:522.)
    47. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med 2017; 377:1824.
    48. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med 2017; 377:1813.